Laura
Ochoa Callejero
Publikationen (37) Publikationen von Laura Ochoa Callejero
2022
-
CCL5 Levels Predict Stroke Volume Growth in Acute Ischemic Stroke and Significantly Diminish in Hemorrhagic Stroke Patients
International journal of molecular sciences, Vol. 23, Núm. 17
2021
-
Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia
European Journal of Internal Medicine, Vol. 88, pp. 89-95
-
Adrenomedullin is a diagnostic and prognostic biomarker for acute intracerebral hemorrhage
Current Issues in Molecular Biology, Vol. 43, Núm. 1, pp. 324-334
-
Maraviroc prevents hcc development by suppressing macrophages and the liver progenitor cell response in a murine chronic liver disease model
Cancers, Vol. 13, Núm. 19
-
Response to Letter to the Editor from Abobaker and Darrat: "circulating levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients"
Journal of the Endocrine Society
2020
-
Author Correction: Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and less brain damage (Scientific Reports, (2016), 6, 1, (33495), 10.1038/srep33495)
Scientific Reports
-
Macrocybin, a Natural Mushroom Triglyceride, Reduces Tumor Growth In Vitro and In Vivo through Caveolin-Mediated Interference with the Actin Cytoskeleton
Molecules (Basel, Switzerland), Vol. 25, Núm. 24
2018
-
InForm software: A semi-Automated research tool to identify presumptive human hepatic progenitor cells, and other histological features of pathological significance
Scientific Reports, Vol. 8, Núm. 1
-
Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet
Translational Research, Vol. 196, pp. 17-30
2017
-
Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer
Scientific Reports, Vol. 7, Núm. 1
2016
-
Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and more brain damage
Scientific Reports, Vol. 6
-
Off-label use of maraviroc in clinical practice
Expert Review of Anti-Infective Therapy
-
Prevention of bone loss in a model of postmenopausal osteoporosis through adrenomedullin inhibition
Frontiers in Physiology, Vol. 7
-
Temporal profiles of blood pressure, circulating nitric oxide, and adrenomedullin as predictors of clinical outcome in acute ischemic stroke patients
Molecular Medicine Reports, Vol. 13, Núm. 5, pp. 3724-3734
2015
-
Erratum to NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis [Cancer Cell 25, 582-598; (2015)]
Cancer Cell
-
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis
Cancer Cell, Vol. 28, Núm. 5, pp. 582-598
2014
-
Adrenomedullin and tumour microenvironment
Journal of Translational Medicine, Vol. 12, Núm. 1
-
Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout
Cell Death and Differentiation, Vol. 21, Núm. 11, pp. 1721-1732
-
Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)
Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 7, pp. 1903-1910
2013
-
Adrenomedullin Peptides
Handbook of Biologically Active Peptides (Elsevier Inc.), pp. 990-995